Diagnos has agreed to provide services to Miraculins for the development of its cancer diagnostic discovery programs.


Diagnos will help interpret data generated during the biomarker discovery and validation process. The company will leverage its technology to develop and test multiple algorithms with the objective of producing a diagnostic test with the highest possible sensitivity and specificity, resulting in fewer false positives and false negatives.